Health Discovery Corporation (OTCBB: HDVY), a molecular diagnostics company that uses patent protected advanced mathematical techniques for personalized medicine, says its game-changing iPhone app, MelApp, has the potential to change the face of early detection against the world’s fastest growing cancer.

Within just days of release, MelApp is being used by consumers in 24 countries (United States, Canada, Australia, New Zealand, United Kingdom, Italy, Spain, Ireland, Germany, Portugal, Venezuela, Brazil, Switzerland, Sweden, Belgium, Bulgaria, Croatia, Argentina, Netherlands, Romania, Poland, Luxembourg, Greece, Turkey) as reported by tracking data from July 6 to July 10, 2011. Additionally, in just these few days, MelApp has successfully achieved the status of ranking among the top 100 highest grossing apps in 20 countries in the Healthcare and Fitness category. Health Discovery Corporation is particularly pleased to see early sales from New Zealand and Australia, which have some of the highest rates of skin cancer in the world.

“Most consumers understand that early detection is critical with a cancer like Melanoma; what they need is a reliable technology literally at their fingertips that offers immediate convenience at an affordable price. Now they have it with MelApp,” explains Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “We are particularly pleased with the rate of downloads and global reach achieved thus far especially since we purposefully released MelApp initially as a soft launch. It’s a rewarding scenario that Health Discovery Corporation finds itself in, both for the consumers who download and use this informative app and our shareholders who could benefit from the revenue being generated by global product sales of MelApp.”

Herbert A Fritshe, PhD, Chief Science Officer for Health Discovery Corp and retired Professor of Laboratory Medicine at MD Anderson Cancer Center, states, "The rapid worldwide use of MelApp appears to be proof that consumers are interested in learning more about their risk of melanoma. It is our hope that with the knowledge learned from MelApp, these consumers will seek earlier medical diagnosis and treatment when their melanoma is largely curable, ultimately potentially saving their life."